Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 8NIH 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 35Lymphoma, Follicular 30Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Pancreatic Neoplasms 15Neoplasm Metastasis 15Leukemia 15Squamous Cell Carcinoma of Head and Neck 12Melanoma 12Stomach Neoplasms 11Colorectal Neoplasms 11Lymphoma, B-Cell, Marginal Zone 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × Cyclophosphamide × Clear all
NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Intima Bioscience, Inc.

Phase 1/2 Completed
23 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT00381173 2013-05-14

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Eisai Inc.

Phase 1 Completed
22 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡